Patents Assigned to Heska Corporation
-
Patent number: 6905682Abstract: The present invention relates to flea allantoinase proteins; to flea allantoinase nucleic acid molecules, including those that encode such flea allantoinase proteins; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit flea allantoinase activity, as well as the use of such therapeutic compositions to treat animals.Type: GrantFiled: June 25, 2002Date of Patent: June 14, 2005Assignee: Heska CorporationInventors: Patrick J. Gaines, Nancy Wisnewski
-
Patent number: 6905845Abstract: Isolated nucleic acids encoding allergens of the species Dermatophagoides pteronyssinus and Dermatophagoides farinae, Der p VII and Der f VII, respectively, are disclosed. A cDNA encoding a peptide having a Der p VII activity and a predicted molecular weight of about 22, 177 daltons is described. A cDNA encoding a peptide having Der f VII activity is also described. The nucleic acid of the invention can be used as probes to detect the presence of Der p VII or Der f VII nucleotide acid in a sample or for the recombinant production of peptides having a Der p VII or Der f VII activity. Peptides having a Der p VII or Der f VII activity can be used in compositions suitable for pharmaceutical administration or methods of diagnosing sensitivity to house dust mite allergens.Type: GrantFiled: December 19, 2001Date of Patent: June 14, 2005Assignee: Heska CorporationInventors: Wayne Robert Thomas, Kaw-Yan Chua
-
Patent number: 6887672Abstract: The present invention relates to equine Fc epsilon receptor alpha chain nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes methods to detect IgE using such proteins and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to mediate Fc epsilon receptor-mediated biological responses.Type: GrantFiled: May 8, 2003Date of Patent: May 3, 2005Assignee: Heska CorporationInventors: Eric R. Weber, Catherine A. McCall
-
Patent number: 6852847Abstract: The present invention relates to canine and feline B7 proteins; to B7 nucleic acid molecules, including those that encode such B7 proteins; to antibodies raised against such B7 proteins; and to therapeutic compounds that regulate B7 function. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.Type: GrantFiled: March 19, 1999Date of Patent: February 8, 2005Assignee: Heska CorporationInventors: Gek-Kee Sim, Shumin Yang, Karen S. Sellins
-
Patent number: 6818444Abstract: The present invention relates to canine and feline proteins. In particular, the present invention discloses feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain proteins. The present invention also includes feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain nucleic acid molecules encoding such proteins, antibodies raised against such proteins and/or inhibitors of such proteins or nucleic acid molecules. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and/or inhibitors, as well as their use to evaluate and regulate an immune response in an animal.Type: GrantFiled: July 27, 2001Date of Patent: November 16, 2004Assignee: Heska CorporationInventors: Ramani S. Wonderling, Karen L. Boroughs
-
Publication number: 20040191868Abstract: The present invention relates to canine interleukin-5 proteins; canine interleukin-5 nucleic acid molecules, including those that encode canine interleukin-5 proteins; to antibodies raised against such proteins; and to inhibitory compounds that regulate such proteins. The present invention also includes methods to identify and obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to regulate an immune response in an animal.Type: ApplicationFiled: February 24, 2004Publication date: September 30, 2004Applicant: Heska CorporationInventors: Shumin Yang, Catherine A. McCall, Eric R. Weber
-
Patent number: 6773712Abstract: The present invention relates to: parasitic helminth cuticlin proteins; parasitic helminth cuticlin nucleic acid molecules, including those that encode such cuticlin proteins; antibodies raised against such cuticlin proteins; and compounds that inhibit parasitic helminth cuticlin activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.Type: GrantFiled: January 22, 2002Date of Patent: August 10, 2004Assignee: Heska CorporationInventors: Ramaswamy Chandrashekar, Tony H. Morales
-
Patent number: 6770282Abstract: The present invention relates to a method to introduce a nucleic acid molecule into a felid by administration of a nucleic acid-cationic lipid complex composition. The method includes the step of administering to the felid, by a parenteral route, a nucleic acid-cationic lipid complex to elicit and/or enhance an immune response. In one embodiment, this method enhances the immune response in a felid compared to a method in which a naked DNA vaccine is administered to a felid. Also provided is a method to deliver a nucleic acid to a felid. This method comprises parenterally administering to the felid a composition that includes a nucleic acid molecule complexed with a cationic lipid.Type: GrantFiled: August 10, 2001Date of Patent: August 3, 2004Assignee: Heska CorporationInventors: Joel R. Haynes, Ramani S. Wonderling, Dan T. Stinchcomb
-
Patent number: 6703360Abstract: The invention relates to canine immunoglobulin G (IgG) and canine interleukin-13 receptors (IL-13R) as well as fusion proteins containing canine IgG and/or canine IL-13R. In particular, the present invention discloses nucleic acid molecules encoding canine IgG, including species-specific regions of the heavy chain of canine IgG, and canine IL-13R alpha chain (IL-13R&agr;) proteins, particularly canine interleuken receptor alpha 1 (IL-13R&agr;1) and canine interleuken receptor alpha 2 (IL-13R&agr;2) proteins. Also included are canine IgG and IL-13R&agr; proteins, antibodies having selectivity for such proteins, inhibitors of such proteins and/or nucleic acid molecules, cells transformed with said nucleic acid molecules, assays employing such cells, nucleic acids molecules, proteins, antibodies and/or inhibitors, and therapeutic compositions comprising said nucleic acids molecules, proteins, antibodies and/or inhibitors.Type: GrantFiled: April 9, 2001Date of Patent: March 9, 2004Assignee: Heska CorporationInventors: Catherine A. McCall, Liang Tang
-
Patent number: 6682894Abstract: The present invention includes a method to detect IgE using a human Fc epsilon receptor (Fc&egr;R) to detect IgE antibodies in a biological sample from a cat, a dog, or a horse. The present invention also relates to kits to perform such methods.Type: GrantFiled: August 30, 2001Date of Patent: January 27, 2004Assignee: Heska CorporationInventors: Glenn R. Frank, James P. Porter, Keith E. Rushlow, Donald L. Wassom
-
Patent number: 6673345Abstract: The present invention relates to parasite astacin metalloendopeptidase proteins, nucleic acid molecules having sequences that encode such proteins, antibodies raised against such proteins and compounds that can inhibit the activities of parasite astacin metalloendopeptidases. The present invention also includes methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitors. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites, such as heartworm infection.Type: GrantFiled: May 23, 2001Date of Patent: January 6, 2004Assignee: Heska CorporationInventors: Cynthia Ann Tripp, Glenn Robert Frank, Robert B. Grieve
-
Patent number: 6673916Abstract: The present invention relates to parasitic helminth PLA2 proteins; to parasitic helminth PLA2 nucleic acid molecules, including those that encode such proteins; to antibodies raised against such proteins; and to compounds that inhibit parasitic helminth phospholipase A2 activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitors. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies, and/or inhibitors as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.Type: GrantFiled: September 7, 1999Date of Patent: January 6, 2004Assignees: Colorado State University Research Foundation, Heska CorporationInventors: Robert B. Grieve, Glenn R. Frank, Nancy Wisnewski
-
Patent number: 6664090Abstract: The present invention relates to arthropod esterase proteins; to arthropod esterase nucleic acid molecules, including those that encode such esterase proteins; to antibodies raised against such esterase proteins; and to other compounds that inhibit arthropod esterase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from hematophagous arthropod infestation.Type: GrantFiled: May 2, 2000Date of Patent: December 16, 2003Assignee: Heska CorporationInventors: Gary M. Silver, Nancy Wisnewski, Kevin S. Brandt
-
Patent number: 6638744Abstract: The present invention relates to canine COX-1 and COX-2 proteins; to canine COX-1 and COX-2 nucleic acid molecules, including those that encode such COX-1 and COX-2 proteins, respectively; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit COX-2 activity, as well as the use of such therapeutic compositions to treat animals.Type: GrantFiled: July 31, 2001Date of Patent: October 28, 2003Assignee: Heska CorporationInventors: Nancy Wisnewski, Kevin S. Brandt
-
Publication number: 20030185755Abstract: The present invention is directed to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal. The present invention includes a saliva protein collection apparatus capable of collecting ectoparasite saliva proteins substantially free of contaminating material. The present invention also relates to ectoparasite saliva proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to obtain such proteins and to use such proteins to identify animals susceptible to or having allergic dermatitis. The present invention also includes therapeutic compositions comprising such proteins and their use to treat animals susceptible to or having allergic dermatitis.Type: ApplicationFiled: October 14, 2002Publication date: October 2, 2003Applicant: Heska Corporation.Inventors: Glenn R. Frank, Shirley W. Hunter, Lynda Wallenfels
-
Patent number: 6586173Abstract: The present invention relates to parasitic helminth aromatic amino acid decarboxylase proteins; to parasitic helminth aromatic amino acid decarboxylase nucleic acid molecules, including those that encode such aromatic amino acid decarboxylase proteins; to antibodies raised against such aromatic amino acid decarboxylase proteins; and to compounds that inhibit parasitic helminth aromatic amino acid decarboxylase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by filariids. The present invention also includes a method for detecting the presence of amino acid decarboxylases.Type: GrantFiled: February 5, 2001Date of Patent: July 1, 2003Assignee: Heska CorporationInventor: Liang Tang
-
Patent number: 6582701Abstract: The present invention relates to equine Fc epsilon receptor alpha chain nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes methods to detect IgE using such proteins and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to mediate Fc epsilon receptor-mediated biological responses.Type: GrantFiled: February 29, 2000Date of Patent: June 24, 2003Assignee: Heska CorporationInventors: Eric R. Weber, Catherine A. McCall
-
Patent number: 6576750Abstract: The present invention relates to flea peritrophin proteins; to flea peritrophin nucleic acid molecules, including those that encode such flea peritrophin proteins; to antibodies raised against such proteins; and to compounds that inhibit the activity of such proteins. The present invention also includes methods to obtain and use such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. The present invention also includes therapeutic compositions comprising such inhibitory compounds, particularly those that specifically inhibit flea peritrophin activity, as well as the use of such therapeutic compositions to treat animals.Type: GrantFiled: October 11, 2000Date of Patent: June 10, 2003Assignee: Heska CorporationInventors: Patrick J. Gaines, Nancy Wisnewski
-
Patent number: 6576238Abstract: The present invention is directed to a novel product and method for isolating ectoparasite saliva proteins, and a novel product and method for detecting and/or treating allergic dermatitis in an animal. The present invention also relates to ectoparasite saliva proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to obtain such proteins and to use such proteins to identify animals susceptible to or having allergic dermatitis. The present invention also includes therapeutic compositions comprising such proteins and their use to treat animals susceptible to or having allergic dermatitis.Type: GrantFiled: August 27, 1998Date of Patent: June 10, 2003Assignee: Heska CorporationInventors: Eric R. Weber, Shirley Wu Hunter, Glenn Robert Frank, Lynda Wallenfels
-
Patent number: 6573372Abstract: The invention relates to: nucleic acid molecules encoding the light chain and heavy chain of feline immunoglobulin E (IgE), including species-specific regions of feline IgE; proteins encoded by the nucleic acid molecules; inhibitors to the nucleic acids and proteins; antibodies to the proteins; cells transformed with the nucleic acid molecules; assays employing the transformed cells, nucleic acids, antibodies and/or proteins or portions thereof; methods for treating IgE-mediated responses (ie. allergy) using the materials provided; methods for eliciting an immune response to IgE and kits containing the nucleic acid molecules, proteins or derivatives thereof (ie. antibodies).Type: GrantFiled: January 7, 2000Date of Patent: June 3, 2003Assignee: Heska CorporationInventors: Catherine McCall, Eric Weber